Aglaris Appoints New CEO
Aglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Entries by Michael Kuhrt
Exscientia Appoints Georgy Egorov as CFO
Exscientia, a company in Artificial Intelligence (AI)-driven drug discovery, has announced the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO).
Pfizer CEO announces Succession
Pfizer Inc. today announced its Board of Directors has unanimously elected Dr. Albert Bourla, 56, Pfizer Chief Operating Officer (COO), to succeed Ian Read as CEO effective January 1, 2019. Ian Read will transition from his current role as Chairman and CEO to Executive Chairman of Pfizer’s Board of Directors.
Formulation matters
Back in February 2017, CDMO Rentschler Biopharma SE and formulation specialist Leukocare AG joined forces to give biologics and biosimilar makers a competitive edge through significantly stabilised end products. European Biotechnology spoke with Leukocare’s CEO Michael Scholl about the impact of formulation on drug product performance.
Ysios Capital appoints Guillem Laporta
Ysios Capital, a biotechnology venture capital firm in Spain, today announced that it has appointed Guillem Laporta as Principal.
Turning cancer into a chronic disease
Following last year’s approval by the US FDA, the EU’s EMA has now also approved the first two T-cell-based immunotherapies against certain types of cancer. This marks the ultimate proof-of-concept for the acceptance of patient-individualised cellular immunotherapies. The regulatory authorities have moved fast, together with the companies and manufacturers, to bring these products to patients as quickly as possible. This is a good start but what does the future hold?
Virion Appoints Vanessa King as President & CEO
Virion Biotherapeutics announced the appointments of Vanessa King, PhD, as President & Chief Executive Officer this week.
Carl Bjartmar appointed as CMO for Ascelia Pharma
Ascelia Pharma announced on Friday Spetember 14 that Carl Bjartmar, MD, PhD, has been appointed as new Chief Medical Officer (CMO) for Ascelia Pharma. Carl has most recently worked as CMO for Wilson Therapeutics.
Torbjørn Furuseth joins Targovax as CFO
Targovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovax’s CFO, will become Chief Business Officer, replacing Michael Bogenstaetter
Johanna Ivaska joins Orion Corporation
Johanna Ivaska, Academy Professor of Biochemistry has been appointed Head & Vice President of Oncology Research in Orion Corporation as of 1 October 2018. Ivaska joins Orion from the University of Turku and will continue working also there with her internationally recognised research team.